Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer

Inclusion Criteria

• •Male with original diagnosis of adenocarcinoma of the prostate with prior definitive therapy
• •Suspicion of recurrence or persistence
• •* after radiotherapy or cryotherapy: 3 consecutive PSA rises and/or PSA rise by 2.0 ng/mL or more above nadir (ASTRO-Phoenix)
• •* after prostatectomy, PSA \> 0.2 ng/mL on 2 or more determinations (recurrence), or failure of PSA to fall to undetectable levels post-prostatectomy (persistence) (American Urological Association)
• •For patients who previously had radical prostatectomy, salvage radiotherapy is one likely treatment plan; for patients who initially underwent radiotherapy (including brachytherapy), confirmation of low volume disease is needed to define (local) treatment.
• •Life expectancy of 6 months or more as judged by the investigator
• •Willing and able to undergo all study procedures
• •Informed consent in writing